Tobacco smoke-induced hypercoagulation in human plasma: Role of carbon monoxide

Vance G Nielsen, David T. Hafner, Evangelina B. Steinbrenner

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Virtually every disease state associated with chronic or acute thrombosis has had smoking identified as a risk factor. Further, smoking enhances clot strength as assessed by thrombelastography. Critically, carbon monoxide, a product of cigarette smoking, has been demonstrated to enhance plasmatic coagulation in vitro via modulation of a heme associated with fibrinogen. We hypothesized that plasmatic hypercoagulability and formation of carboxyhemefibrinogen (COHF) detected with thrombelastographic methods would be observed after cigarette smoking. Smoking participants (n=20, two cigarettes consumed within 90âŠmin, average carboxyhemoglobin concentration of 5%) had plasma collected and normal participant (n=20) plasma was also obtained. Thrombelastographic analyses revealed that plasma obtained from smokers had an 86% greater velocity of clot growth and 65% larger clot strength than normal participant plasma. Forty-five percent of smokers had plasma clot strength that exceeded the 95th percentile of normal participant plasma values; 45% of smoking participants had detectable COHF; and 20% of smoking participants were both hypercoagulable with COHF present. We conclude that smoking induced a hypercoagulable state and COHF formation in an important portion of participants tested. Future investigations of the effects of smoking, plasmatic hypercoagulation and COHF formation are planned in populations with established atherosclerotic/thrombotic disease.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalBlood Coagulation and Fibrinolysis
Volume24
Issue number4
DOIs
StatePublished - Jun 2013

Fingerprint

Carbon Monoxide
Smoke
Tobacco
Smoking
Thrombelastography
Carboxyhemoglobin
Thrombophilia
Heme
Tobacco Products
Fibrinogen
Thrombosis
Growth

Keywords

  • carbon monoxide
  • smoking
  • thrombelastography
  • thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Tobacco smoke-induced hypercoagulation in human plasma : Role of carbon monoxide. / Nielsen, Vance G; Hafner, David T.; Steinbrenner, Evangelina B.

In: Blood Coagulation and Fibrinolysis, Vol. 24, No. 4, 06.2013, p. 405-410.

Research output: Contribution to journalArticle

Nielsen, Vance G ; Hafner, David T. ; Steinbrenner, Evangelina B. / Tobacco smoke-induced hypercoagulation in human plasma : Role of carbon monoxide. In: Blood Coagulation and Fibrinolysis. 2013 ; Vol. 24, No. 4. pp. 405-410.
@article{720b2906b3db489889c0419fcd4f718a,
title = "Tobacco smoke-induced hypercoagulation in human plasma: Role of carbon monoxide",
abstract = "Virtually every disease state associated with chronic or acute thrombosis has had smoking identified as a risk factor. Further, smoking enhances clot strength as assessed by thrombelastography. Critically, carbon monoxide, a product of cigarette smoking, has been demonstrated to enhance plasmatic coagulation in vitro via modulation of a heme associated with fibrinogen. We hypothesized that plasmatic hypercoagulability and formation of carboxyhemefibrinogen (COHF) detected with thrombelastographic methods would be observed after cigarette smoking. Smoking participants (n=20, two cigarettes consumed within 90{\^a}Šmin, average carboxyhemoglobin concentration of 5{\%}) had plasma collected and normal participant (n=20) plasma was also obtained. Thrombelastographic analyses revealed that plasma obtained from smokers had an 86{\%} greater velocity of clot growth and 65{\%} larger clot strength than normal participant plasma. Forty-five percent of smokers had plasma clot strength that exceeded the 95th percentile of normal participant plasma values; 45{\%} of smoking participants had detectable COHF; and 20{\%} of smoking participants were both hypercoagulable with COHF present. We conclude that smoking induced a hypercoagulable state and COHF formation in an important portion of participants tested. Future investigations of the effects of smoking, plasmatic hypercoagulation and COHF formation are planned in populations with established atherosclerotic/thrombotic disease.",
keywords = "carbon monoxide, smoking, thrombelastography, thrombosis",
author = "Nielsen, {Vance G} and Hafner, {David T.} and Steinbrenner, {Evangelina B.}",
year = "2013",
month = "6",
doi = "10.1097/MBC.0b013e32835d5458",
language = "English (US)",
volume = "24",
pages = "405--410",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Tobacco smoke-induced hypercoagulation in human plasma

T2 - Role of carbon monoxide

AU - Nielsen, Vance G

AU - Hafner, David T.

AU - Steinbrenner, Evangelina B.

PY - 2013/6

Y1 - 2013/6

N2 - Virtually every disease state associated with chronic or acute thrombosis has had smoking identified as a risk factor. Further, smoking enhances clot strength as assessed by thrombelastography. Critically, carbon monoxide, a product of cigarette smoking, has been demonstrated to enhance plasmatic coagulation in vitro via modulation of a heme associated with fibrinogen. We hypothesized that plasmatic hypercoagulability and formation of carboxyhemefibrinogen (COHF) detected with thrombelastographic methods would be observed after cigarette smoking. Smoking participants (n=20, two cigarettes consumed within 90âŠmin, average carboxyhemoglobin concentration of 5%) had plasma collected and normal participant (n=20) plasma was also obtained. Thrombelastographic analyses revealed that plasma obtained from smokers had an 86% greater velocity of clot growth and 65% larger clot strength than normal participant plasma. Forty-five percent of smokers had plasma clot strength that exceeded the 95th percentile of normal participant plasma values; 45% of smoking participants had detectable COHF; and 20% of smoking participants were both hypercoagulable with COHF present. We conclude that smoking induced a hypercoagulable state and COHF formation in an important portion of participants tested. Future investigations of the effects of smoking, plasmatic hypercoagulation and COHF formation are planned in populations with established atherosclerotic/thrombotic disease.

AB - Virtually every disease state associated with chronic or acute thrombosis has had smoking identified as a risk factor. Further, smoking enhances clot strength as assessed by thrombelastography. Critically, carbon monoxide, a product of cigarette smoking, has been demonstrated to enhance plasmatic coagulation in vitro via modulation of a heme associated with fibrinogen. We hypothesized that plasmatic hypercoagulability and formation of carboxyhemefibrinogen (COHF) detected with thrombelastographic methods would be observed after cigarette smoking. Smoking participants (n=20, two cigarettes consumed within 90âŠmin, average carboxyhemoglobin concentration of 5%) had plasma collected and normal participant (n=20) plasma was also obtained. Thrombelastographic analyses revealed that plasma obtained from smokers had an 86% greater velocity of clot growth and 65% larger clot strength than normal participant plasma. Forty-five percent of smokers had plasma clot strength that exceeded the 95th percentile of normal participant plasma values; 45% of smoking participants had detectable COHF; and 20% of smoking participants were both hypercoagulable with COHF present. We conclude that smoking induced a hypercoagulable state and COHF formation in an important portion of participants tested. Future investigations of the effects of smoking, plasmatic hypercoagulation and COHF formation are planned in populations with established atherosclerotic/thrombotic disease.

KW - carbon monoxide

KW - smoking

KW - thrombelastography

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84877691085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877691085&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e32835d5458

DO - 10.1097/MBC.0b013e32835d5458

M3 - Article

C2 - 23429254

AN - SCOPUS:84877691085

VL - 24

SP - 405

EP - 410

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 4

ER -